New hope for stem cell transplant patients with severe immune complication

NCT ID NCT06824103

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGvHD) that did not improve with steroids. cGvHD is a condition where donor immune cells attack the patient's body after a stem cell transplant. The goal is to see if ruxolitinib can help control the disease without needing additional treatments. About 50 participants will take the drug and be monitored for response and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VS. HOST DISEASE CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE GRAFT VS HOST DISEASE

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Hefei, Anhui, 230001, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Nanning, Guangxi, 530021, China
Novartis Investigative Site
RECRUITING

Guiyang, Guizhou, 550004, China
Novartis Investigative Site
RECRUITING

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site
RECRUITING

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site
RECRUITING

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710061, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610041, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Ningbo, Zhejiang, 315016, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Changsha, 410000, China
Novartis Investigative Site
RECRUITING

Chongqing, 400016, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Wujiang Nongchang, 065201, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.